US20210015724A1 - Gold and palmitoyl pentapeptide-4 nanoparticles - Google Patents

Gold and palmitoyl pentapeptide-4 nanoparticles Download PDF

Info

Publication number
US20210015724A1
US20210015724A1 US17/042,500 US201917042500A US2021015724A1 US 20210015724 A1 US20210015724 A1 US 20210015724A1 US 201917042500 A US201917042500 A US 201917042500A US 2021015724 A1 US2021015724 A1 US 2021015724A1
Authority
US
United States
Prior art keywords
nanoparticles
peptide
composition
formula
gold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/042,500
Other languages
English (en)
Inventor
Marisabel Mourelle Mancini
Maria Elisa ALEA REYES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinitec Activos SL
Original Assignee
Infinitec Activos SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinitec Activos SL filed Critical Infinitec Activos SL
Assigned to INFINITEC ACTIVOS, S.L. reassignment INFINITEC ACTIVOS, S.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOURELLE MANCINI, MARISABEL, ELISA ALEA REYES, MARIA
Publication of US20210015724A1 publication Critical patent/US20210015724A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/65—Characterized by the composition of the particulate/core
    • A61K2800/654—The particulate/core comprising macromolecular material

Definitions

  • the present invention relates to palmitoyl pentapeptide-4 conjugated gold nanoparticles, compositions comprising them, use thereof in cosmetic treatments, as well as methods for obtaining said nanoparticles.
  • Fine lines appear in different facial areas and are the most easily recognized signs of aging. Fine lines are the first to appear. These small, somewhat shallow wrinkles tend to be noticed in the outer corners of the eyes. They are also known as laugh lines or crow's feet. Fine lines can also be located on the cheeks. On the forehead, wrinkles are noticed as horizontal lines and may be brought out by facial expressions, and they tend to become deeper over time. Smaller sized vertical lines between the eyebrows are caused by furrowing the brow.
  • the topical administration of cosmetic or therapeutic agents is a challenge in the field of cosmetic or pharmaceutical formulations since the skin has low permeability to high molecular weight molecules.
  • the main function of the skin is precisely the regulation of the entrance of substances into the body.
  • the skin of mammals consists of two main layers: the epidermis and the dermis.
  • the epidermis is formed by the stratum corneum, stratum granulosum, stratum spinosum, and stratum basale, the stratum corneum constituting the surface of the skin and the stratum basale constituting the deepest part of the epidermis.
  • the stratum corneum is the layer of skin which contributes the most to the barrier properties and which most obstructs the passage of cosmetically active substances to the deeper layers.
  • nanomaterials such as nanoparticles [Baroli, B. J. Pharm. Sci., 2010, 99(1), 21-50].
  • nanoparticles are lipid nanoparticles, polymer nanoparticles, magnetic nanoparticles, and metallic nanoparticles, among which are included gold nanoparticles [Gupta, R. and Rai, B.; J. Phys. Chem. B, 2016, 120(29), 7133-7142].
  • Said nanoparticles are described as being capable of penetrating deep layers of the skin (epidermis and dermis).
  • Palmitoyl pentapeptide-4 is a peptide of formula Palm-L-Lys-L-Thr-L-Thr-L-Lys-L-Ser-OH (Palm-SEQ ID NO: 1). This peptide is also known by the name Matrixyl®. Said peptide and its anti-wrinkle activity have been described in WO 00/15188 A1.
  • WO 2008/079898 A1 discloses compositions that can comprise a colloidal metal, such as gold, which can be conjugated to a molecule, such as peptides, including Matrixyl®. However, WO 2008/079898 A1 does not disclose any specific composition comprising colloidal gold conjugated to Matrixyl®. This document is also silent about any advantage related to the use of Matrixyl® conjugated with a colloidal metal that would allow obtaining improved compositions for the treatment of wrinkles, in particular compositions having improved penetration of Matrixyl® in deep layers of the skin and improved stability of said peptide.
  • a colloidal metal such as gold
  • the objective of the present invention is to provide improved compositions for the treatment of the wrinkles.
  • conjugating PP-4 peptide (a peptide of formula (I)) with gold nanoparticles achieves penetration of said peptide in deep layers of the skin. Said penetration is surprisingly much greater than that of the peptide of formula (I) in a composition of said peptide and gold nanoparticles without conjugation, as shown in the examples.
  • conjugation of the peptide of formula (I) with gold nanoparticles provides an unexpected stability to the peptide of formula (I), particularly against the enzymatic degradation by proteases.
  • the present invention relates to gold nanoparticles conjugated with a peptide of formula (I):
  • R-SEQ ID NO: 1 R-L-Lys-L-Thr-L-Thr-L-Lys-L-Ser-OH wherein R is a C 10 -C 22 acyl moiety, preferably a palmitoyl moiety.
  • the present invention relates to a composition comprising the nanoparticles defined in the first aspect and water.
  • the present invention relates to the use of nanoparticles as defined in the first aspect in the preparation of a composition as defined in the second aspect.
  • the present invention relates to the (cosmetic) use of nanoparticles as defined in the first aspect or of a composition as defined in the second aspect for skin care.
  • the present invention relates to a method for obtaining nanoparticles as defined in the first aspect, which comprises:
  • FIG. 1 shows the percentage of cutaneous penetration of the different assayed compositions after 20 hours of incubation.
  • the present invention relates to gold nanoparticles conjugated with a peptide of formula (I):
  • R-SEQ ID NO: 1 R-L-Lys-L-Thr-L-Thr-L-Lys-L-Ser-OH wherein R is a C 10 -C 22 acyl moiety, preferably a palmitoyl moiety.
  • acyl refers to a moiety having from 10 to 22 carbon atoms and having the structure R′—C( ⁇ O)—, wherein R′ is a C 9 -C 21 alkyl group.
  • the number of carbon atoms of the acyl group corresponds to the number of carbon atoms of the alkyl substituent R′ plus one carbon atom of the C( ⁇ O) group.
  • Examples of acyl groups are CH 3 (CH 2 ) 14 —C( ⁇ O)— (i.e.
  • the nanoparticles of the present invention have a gold core coated with the peptide of formula (I).
  • conjuggated refers to the gold nanoparticles being bound to the peptide of formula (I) by means of an electrostatic ionic bond established between the negative charges of the gold surface of the nanoparticles and the positive charges of the amino acid Lys (lysine) present in the peptide of formula (I).
  • the positive charge provided by this amino acid to the peptide is responsible for the bond established between the peptide of formula (I) and the gold surface of the nanoparticles, which results in the functionalization thereof where the peptide will coat the outer surface of the gold nanoparticles assuring the formation and stability thereof.
  • nanoparticle refers to particles the mean diameter of which is less than 1000 nm, preferably less than 500 nm, more preferably less than 250 nm, more preferably less than 200 nm, preferably between 1 and 1000 nm, more preferably between 1 and 500 nm, more preferably between 1 and 250 nm, more preferably between 1 and 200 nm, more preferably between 50 and 200 nm, more preferably between 100 and 200 nm, even more preferably between 150 and 200 nm.
  • the size of the nanoparticles can be determined by means of conventional methods in the art, particularly by means of dynamic light scattering (DLS).
  • DLS dynamic light scattering
  • the zeta potential of the nanoparticles of the invention is comprised between ⁇ 5 mV and ⁇ 60 mV, preferably between ⁇ 10 mV and ⁇ 50 mV, more preferably between ⁇ 20 mV and ⁇ 40 mV, even more preferably between ⁇ 30 mV and ⁇ 40 mV.
  • zeta potential refers to a measurement of the surface charge of the nanoparticles.
  • the zeta potential determines the degree of repulsion between adjacent nanoparticles having the same charge. If drops by more than a given value, the attractive forces exceed the repulsive forces and the nanoparticles cluster together.
  • the zeta potential of the nanoparticles can be determined by means of conventional methods in the art, particularly by means of the method described below.
  • the preparation of the samples for determining the Z potential consists of weighing 1 mg if it is powder and it is suspended in 1 mL of milli-Q H 2 O. Whereas in the case of liquid samples, a 100 ⁇ L aliquot of the sample to which 900 ⁇ L of milli-Q H 2 O are added is collected with an automatic pipette. Then the Z potential measurement is taken using DTS1070 plastic cuvettes and Zetasizer Nano ZS series equipment (Malvern Instruments) of the Instituto de Qu ⁇ mica Avanzada de Catalu ⁇ a (Advanced Chemistry Institute of Catalonia), CSIC. Z potential measurements can be taken in triplicate for the purpose of demonstrating the reproducibility thereof.
  • the nanoparticles of the invention have a concentration of peptide of formula (I) from 0.01 to 1 mg per mg of nanoparticles, preferably from 0.01 to 0.5 mg/mg, more preferably from 0.05 to 0.5 mg/mg, more preferably from 0.1 to 0.5 mg/mg, even more preferably from 0.1 to 0.3 mg/mg.
  • the present invention relates to a composition comprising the nanoparticles defined in the first inventive aspect and water.
  • said composition is a dispersion of the nanoparticles in water, i.e., a colloid.
  • a colloid refers to a system formed by two or more phases, a fluid (liquid) and another dispersed phase in the form of particles, the size of which is comprised between 1 and 1000 nm, and therefore, the particles are not visible at the macroscopic level but they are at the microscopic level.
  • the dispersion of the nanoparticles in water i.e., the colloid
  • the composition contains at least 90% of water with respect to the sum of the weight of water and nanoparticles in the composition, preferably at least 95%, more preferably at least 99%, most preferably at least 99.5%.
  • compositions of the invention may further comprise a cosmetic agent selected from the group consisting of surfactants, moisturizing agents, antioxidants, emollients, preservatives, humectants, viscosity modifiers, and a mixture thereof.
  • a cosmetic agent selected from the group consisting of surfactants, moisturizing agents, antioxidants, emollients, preservatives, humectants, viscosity modifiers, and a mixture thereof.
  • a “surfactant” is a substance which decreases the surface tension of a composition with respect to the same composition in the absence of said component and furthermore facilitates the uniform distribution of the composition when it is used.
  • surfactants suitable for the compositions of the invention are lauryl isoquinolinium bromide and isopropyl alcohol, polysorbate 20, steareth-2 (polyethylene glycol ether (2 units) and stearyl alcohol), oleth-2 (polyethylene glycol ether (2 units) and oleyl alcohol), PEG-8 caprylic/capric glycerides (ethoxylated with 8 units of polyethylene glycol), sodium cocoamphoacetate, coconut oil esters—polyglycerol 6, almond oil esters—PEG-8, ammonium cocosulfate and avocado oil esters PEG-11, and mixtures thereof.
  • a “moisturizing agent” refers to a substance which increases the water content of the skin or hair and helps to keep it soft.
  • moisturizing agents suitable for the compositions of the invention are vitis vinifera seed oil, ceramide, glucosylceramide, grape oil esters—PEG-8, glyceryl esters—cocoa butter, shea butter cetyl esters, shea butter glyceride, lauryl cocoate, and mixtures thereof.
  • an “antioxidant” refers to a substance which inhibits or reduces reactions promoted by oxygen, thereby preventing oxidation and rancidity.
  • antioxidants suitable for the compositions of the invention are tocopherol, sodium tocopheryl phosphate, 3-glyceryl ascorbate, acetylcysteine, aloe vera plant extract, ascorbic acid, ascorbyl dipalmitate, ascorbic acid polypeptide, acetyl trihexylcitrate, ascorbyl linoleate, 2-acetylhydroquinone, apo-lactoferrin, ascorbyl glucoside, ascorbyl lactoside, and mixtures thereof.
  • an “emollient” refers to a substance which softens the skin.
  • emollients suitable for the compositions of the invention are apo-lactoferrin, acacia dealbata flower wax, acetylarginine, acetylproline, acetylhydroxyproline, acetylated glycol stearate, algae extract, almond oil esters and propylene glycol, aminopropyltocopheryl phosphate, 1,2,6-hexanetriol, and mixtures thereof.
  • a “preservative” refers to a substance which inhibits the development of microorganisms in the composition.
  • preservatives suitable for the compositions of the invention are phenoxyethanol; a mixture of caprylyl glycol, glyceryl caprylate, glycerin, and phenylpropanol; a mixture of benzyl alcohol, glyceryl caprylate, and glyceryl undecylenate; a mixture of 2,2-hexanediol and caprylyl glycol; a mixture of phenethyl alcohol, and ethylhexylglycerin; a mixture of pentylene glycol, caprylyl glycol, and ethylhexylglycerin.
  • a “humectant” refers to a substance which retains humidity.
  • humectants suitable for the compositions of the invention are 3-glyceryl ascorbate, acetylcyclodextrin, propanediol, algae extract, 2,3-butanediol, 3-ethylhexylglyceryl ascorbate, 3-laurylglyceryl ascorbate, and capryl 3-glyceryl ascorbate.
  • a “viscosity modifier” refers to a substance which increases the viscosity of a composition, preferably an aqueous composition.
  • examples of viscosity modifiers suitable for the compositions of the invention are carbomer, sodium carbomer, dextran sulfate sodium, carboxymethyl chitosan, propanediol, carboxymethyl dextran, steareth-30, steareth-40, steareth-50, sodium poly polynaphthalene sulfonate, croscarmelose, sodium glycereth-polyphosphate, and mixtures thereof.
  • compositions of the invention are in the form of a cream, serum, emulsion, gel, foam, paste, ointment, milk, or solution, preferably in the form of cream, solution, serum or gel.
  • the nanoparticles of the present invention are used in the preparation of a composition according to the present invention.
  • compositions can be prepared by means of mixing the nanoparticles of the invention with the rest of the components of the corresponding compositions.
  • palmitoyl pentapeptide-4 (PP-4, a peptide of formula (I)) presents anti-wrinkle activity [WO 00/15188 A1].
  • the present invention relates to the use of the nanoparticles or compositions of the invention in skin care. Said use is cosmetic.
  • care refers to the maintenance or improvement of the qualities of the skin, such as wrinkles, elasticity, firmness, hydration, shine, tone, or texture, among others, preferably wrinkles.
  • skin care is the cosmetic treatment of wrinkles and/or cosmetic prevention of the onset of wrinkles.
  • treatment refers to a non-therapeutic cosmetic treatment, in which the application of the composition of the invention on improves the cosmetic appearance of the skin in terms of wrinkles, by either reducing the depth of the wrinkles, reducing the number of wrinkles, or both.
  • prevention refers to the capability of the composition of the invention to prevent, delay, or impede the onset of wrinkles in the skin.
  • the present invention relates to a method for obtaining nanoparticles of the invention, which comprises:
  • the gold nanoparticles are formed in step (a).
  • the reducing agent of step (a) is selected from the group consisting of sodium citrate, NaBH 4 , H 2 O 2 , hydroxylamines (such as for example hydroxylamine sulfate, hydroxylamine-O-sulfonic acid, and hydroxylamine hydrochloride), tetrahydropyridines (such as for example, 1,3-bis(4-octadecyloxy-1,2,5,6-tetrahydropyridylmethyl)benzene), 1,3-bis(4-decyloxy-1,2,5,6-tetrahydropyridylmethyl)benzene) and 1,3-bis(4-methyl-1,2,5,6-tetrahydropyridylmethyl)benzene), oxalic acid, citric acid, and ascorbic acid; preferably the reducing agent is sodium citrate.
  • hydroxylamines such as for example hydroxylamine sulfate, hydroxylamine-O-sulfonic acid
  • step (a) is carried out in a solvent selected from the group consisting of water, toluene, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, acetone, ethanol, methanol, and mixtures thereof; preferably in water.
  • a solvent selected from the group consisting of water, toluene, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, acetone, ethanol, methanol, and mixtures thereof; preferably in water.
  • the reduction reaction of step (a) is carried out at a temperature between 80° C. and 120° C., more preferably between 90° C. and 110° C., even more preferably between 95° C. and 105° C., most preferably at about 100° C.
  • the compound of Au(III) which is reduced to Au(0) in step (a) is selected from the group consisting of gold (III) oxide (Au 2 O 3 ), gold halides including AuCl 3 and AuBr 3 , preferably the compound of Au(III) is HAuCl 4 .
  • step (b) of treatment with the peptide of formula (I) is performed.
  • said treatment is performed by means of stirring a mixture, generally a dispersion, of the obtained gold nanoparticles and the peptide of formula (I).
  • Said treatment is preferably performed by adding the peptide (I) to the reaction mixture of the gold nanoparticle formation.
  • the method of step (b) is carried out in a solvent selected from the group consisting of water, toluene, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, acetone, ethanol, methanol, and mixtures thereof, preferably in water.
  • a solvent selected from the group consisting of water, toluene, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, acetone, ethanol, methanol, and mixtures thereof, preferably in water.
  • the treatment is performed by stirring at a temperature between 15° C. and 30° C., preferably between 20° C. and 25° C. Particularly, said stirring is maintained for 3 to 5 h, preferably for about 4 h.
  • the UV-visible spectrum of the three samples of gold nanoparticles were determined in water using a UV-1800 Shimadzu spectrophotometer (Parc Cientific of Barcelona) and quartz cuvettes (Hellma Analytics). The UV-visible spectrum of each sample was determined in water at a concentration of 1 mg/mL.
  • the size of the nanoparticles was determined by dynamic light scattering (DLS) for which quartz cuvettes and Zetasizer Nano ZS series equipment (Malvern Instruments, Instituto de Qu ⁇ mica Avanzada de Catalu ⁇ a) were used.
  • the preparation of the samples consists of 1 mg if it is powder and it is suspended in 1 mL of milli-Q H 2 O.
  • a 100 ⁇ L aliquot of the sample to which 900 ⁇ L of milli-Q H 2 O are added is collected with an automatic pipette such that there is always a concentration of 1 mg/mL of sample.
  • the particle size measurement is taken at a temperature of 25° C. The measurements were taken in triplicate for the purpose of demonstrating the reproducibility thereof.
  • the Z potential of the nanoparticles synthesized was determined using DTS1070 plastic cuvettes and Zetasizer Nano ZS series equipment (Malvern Instruments, of the Instituto de Qu ⁇ mica Avanzada de Catalu ⁇ a, CSIC).
  • the preparation of the samples consists of 1 mg if it is powder and it is suspended in 1 mL of milli-Q H 2 O.
  • a 100 ⁇ L aliquot of the sample to which 900 ⁇ L of milli-Q H 2 O are added is collected with an automatic pipette such that there is always a concentration of 1 mg/mL of sample.
  • the Z potential measurement is taken at a temperature of 25° C. The measurements were taken in triplicate for the purpose of demonstrating the reproducibility thereof.
  • the gold nanoparticles (Examples 1-3) were synthesized using the Turkevich method based on the reduction of Au(III) to Au(0) using sodium citrate as reducing agent and the peptide of corresponding formula as stabilizing agent or in the absence of peptide:
  • the gold nanoparticles (GNP, GNP-P1, and GNP-P2) were synthesized as follows:
  • the dispersion was maintained under stirring for 4 h, thereby assuring suitable functionalization of the peptide of formula (I) or (II) on the gold surface, obtaining the gold nanoparticles called GNP-P1 and/or GNP-P2, respectively.
  • the concentration of the peptide (P1 or P2) incorporated in the nanoparticles (GNP-P1 and/or GNP-P2) was determined by HPLC, using a Waters 996 photodiode array detector instrument equipped with a Waters 2695 separation module and Millenium software. An Xbridge BEH130 C18 4.6 ⁇ 100 mm 3.5 ⁇ m reverse phase HPLC column by Waters was used. UV detection was performed at 220 nm, and a mobile phase B gradient of 5 to 100% was performed for 8 minutes at a flow rate of 1.0 ml/min. Under these conditions, the retention time being 6.4 min for both peptides P1 and P2. Mobile phase A: 0.045% of TFA/H 2 O, mobile phase B: 0.036% of TFA/ACN.
  • compositions of the peptide of formula (I) (P1; Example 4) and of the peptide of formula (II) (P2; Example 5) were also prepared in the absence of nanoparticles by dissolving the corresponding peptide in water.
  • 0.3 mg of the peptides of formula (I) (P1) and/or (II) (P2) were dissolved in 1 mL of water to have the same peptide concentration in the nanoparticles and in the absence thereof (0.3 mg/mL).
  • GNPs gold nanoparticles
  • P1 peptide of formula (I)
  • the nanoparticles were characterized by UV-visible absorption spectroscopy, DLS (Dynamic Light Scattering), and zeta potential.
  • Nanoparticle Zeta of peptide in diameter potential nanoparticles Example (nm) (mV) (mg/mL) 1 GNP-P1 150-200 ⁇ 35 0.3 2 GNP-P2 150-200 ⁇ 59 0.3 3 GNP 20-50 ⁇ 40 —
  • Cutaneous penetration was determined using Franz cells.
  • the pig skin samples used in the experiments were cut into circles 3 cm in diameter.
  • the pig skin was mounted on the receptor compartment of a Franz diffusion cell system with the stratum corneum facing up towards the donor compartment. 18 ml of phosphate-buffered saline (PBS) were used as receptor solution.
  • An aliquot of the test samples (nanoparticles of Example 1 (GNP-P1), nanoparticles of Example 2 (GNP-P2), nanoparticles of Example 3 (GNP), formulation of peptide P1 of Example 4, formulation of peptide P2 of Example 5, mixture of nanoparticles and peptide P1 (GNP+P1) of Example 6 was applied on the pig skin.
  • the Franz diffusion cells were mounted on an H+P Labortechnik Varimag Telesystem (Munich, Germany) and placed in a thermostatic bath (Haake).
  • Untreated skin control was also included.
  • the Franz diffusion cells were kept at 32° C., and after 20 h of incubation, the receptor solution was analyzed by means of UV-visible absorption spectroscopy using a Shimadzu spectrophotometer UV-1800 (Parc Cientific of Barcelona) and quartz cuvettes (Hellma Analytics) to quantify the amount of gold nanoparticles present (GNP, GNP-P1, and GNP-P2).
  • the amount of free peptide (P1, P2) was determined by means of HPLC, using a Waters 996 photodiode array detector instrument equipped with a Waters 2695 separation module and Millenium software.
  • An Xbridge BEH130 C18 4.6 ⁇ 100 mm 3.5 ⁇ m reverse phase HPLC column by Waters was used.
  • UV detection was performed at 220 nm.
  • Peptide P1 was analyzed with a mobile phase B gradient of 5 to 100% for 8 minutes at a flow rate of 1.0 ml/min, the retention time being 6.5 minutes.
  • Peptide P2 was analyzed with a mobile phase B gradient of 0 to 20% for 8 minutes at a flow rate of 1.0 ml/min, the retention time being 1.5 minutes.
  • the eluents used in both cases were: Mobile phase A: 0.045% of TFA/H 2 O, mobile phase B: 0.036% of TFA/ACN.
  • FIG. 1 Penetration results after 20 h of incubation are shown in FIG. 1 . As can be seen, there is a considerable increase in penetration upon conjugating the peptide of formula (I) with gold nanoparticles. However, said increase in penetration is not observed with the peptide of formula (II).
  • peptide (1) (Example 4; P1) only penetrated the outermost layers external of the skin, whereas in the case of skins treated with the gold nanoparticle (Example 1; GNP-P1), a high content of the peptide-conjugated nanoparticle was achieved, indicating that penetration reached more internal layers such as the epidermis and dermis.
  • Papain (Fagon, Spain) was added (20 mg to the free peptide solutions or 1.5 mg to the nanoparticle solutions). The resulting solutions were incubated at 40° C. Samples were taken at study times (0 h, 0.33 h, 3 h and 24 h after the addition of papain), centrifuged at 1400 rpm for 1 min, and the supernatant was filtered using a 0.45 ⁇ m filter and analyzed by HPLC.
  • HPLC analysis was carried out in a Waters 996 photodiode array detector instrument equipped with a Waters 2695 separation module and Millenium software; an Xbridge BEH130 C18 4.6 ⁇ 100 mm 3.5 ⁇ m reverse phase column by Waters was used. UV detection was performed at 220 nm and a mobile phase B gradient of 5 to 100% was used for 8 minutes at 1.0 ml/min of flow. Under these conditions, the retention time of P1 is 6.4 min. Mobile phase A: 0.045% TFA/H 2 O, mobile phase B: 0.036% TFA/acetonitrile.
  • the peptide of formula (I) conjugated with gold nanoparticles has an unexpected stability against the degradation with papain, whereas the peptide of formula (I) alone (P1) or in combination with gold nanoparticles but without conjugation (GNP+P1) rapidly degrades. Additionally, the peptide of formula (II) conjugated with gold nanoparticles (GNP-P2) also degrades rapidly by the action of papain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US17/042,500 2018-03-28 2019-03-27 Gold and palmitoyl pentapeptide-4 nanoparticles Abandoned US20210015724A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201830311 2018-03-28
ES201830311A ES2726000A1 (es) 2018-03-28 2018-03-28 Nanopartículas de oro y palmitoíl pentapéptido-4
PCT/EP2019/057695 WO2019185696A1 (fr) 2018-03-28 2019-03-27 Nanoparticules d'or et de palmitoyl pentapeptine-4

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/057695 A-371-Of-International WO2019185696A1 (fr) 2018-03-28 2019-03-27 Nanoparticules d'or et de palmitoyl pentapeptine-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/311,704 Continuation US20230270636A1 (en) 2018-03-28 2023-05-03 Gold and palmitoyl pentapeptide-4 nanoparticles

Publications (1)

Publication Number Publication Date
US20210015724A1 true US20210015724A1 (en) 2021-01-21

Family

ID=65991812

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/042,500 Abandoned US20210015724A1 (en) 2018-03-28 2019-03-27 Gold and palmitoyl pentapeptide-4 nanoparticles
US18/311,704 Pending US20230270636A1 (en) 2018-03-28 2023-05-03 Gold and palmitoyl pentapeptide-4 nanoparticles

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/311,704 Pending US20230270636A1 (en) 2018-03-28 2023-05-03 Gold and palmitoyl pentapeptide-4 nanoparticles

Country Status (4)

Country Link
US (2) US20210015724A1 (fr)
EP (1) EP3773462B1 (fr)
ES (2) ES2726000A1 (fr)
WO (1) WO2019185696A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101544B1 (fr) * 2019-10-07 2023-09-29 Sederma Sa Traitement cosmétique ou dermatologique a base de peptide(s) de la peau et de ses phanères
EP3936138A1 (fr) 2020-07-09 2022-01-12 Bella Aurora Labs, S.A. Composition pharmaceutique pour le traitement du vitiligo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079898A1 (fr) * 2006-12-20 2008-07-03 Pharmwest, Inc. Méthodes et formulations topiques comprenant un métal colloïdal servant à traiter ou prévenir des affections cutanées
EP2228393A1 (fr) * 2008-01-04 2010-09-15 Endor Nanotechnologies, S.L. Conjugué d'acide hyaluronique destiné au traitement cosmétique et procédé de préparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2783169B1 (fr) * 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
AU2007353340A1 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
US8097581B2 (en) * 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
KR101333209B1 (ko) * 2011-06-17 2013-11-26 부산대학교 산학협력단 파이토케미컬로 표면처리된 금나노입자를 유효성분으로 함유하는 피부노화방지용 화장료 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079898A1 (fr) * 2006-12-20 2008-07-03 Pharmwest, Inc. Méthodes et formulations topiques comprenant un métal colloïdal servant à traiter ou prévenir des affections cutanées
EP2228393A1 (fr) * 2008-01-04 2010-09-15 Endor Nanotechnologies, S.L. Conjugué d'acide hyaluronique destiné au traitement cosmétique et procédé de préparation

Also Published As

Publication number Publication date
ES2921251T3 (es) 2022-08-22
ES2726000A1 (es) 2019-10-01
US20230270636A1 (en) 2023-08-31
EP3773462A1 (fr) 2021-02-17
WO2019185696A1 (fr) 2019-10-03
EP3773462B1 (fr) 2022-05-11

Similar Documents

Publication Publication Date Title
US20230270636A1 (en) Gold and palmitoyl pentapeptide-4 nanoparticles
RU2517594C2 (ru) Композиции и способы ухода за кожей
EP2624806B1 (fr) Compositions cosmetiques de soin de la peau
US9895302B2 (en) Finasteride polymeric nanoparticle, aqueous suspension containing the same, composition for the treatment of alopecia, process of preparation of said composition, and its use
TW200303764A (en) Cosmetic and/or dermatological use of a composition comprising at least one oxidation-sensitive hydrophilic active principle stabilized by at least one N-vinylimidazole polymer or copolymer
SA515360084B1 (ar) جسيمات بوليمرية بحجم النانو من فيناستيريد ومينوكسيدول، وطريقة لتحضيرها، ومعلق مائييحتوي عليها وتركيبة صيدلانية واستخدامها
KR20000069087A (ko) 화장 조성물
JPH11503165A (ja) レチノイド類とリポソームを含有するスキンケア組成物
US10532024B2 (en) Topical compositions of Lithospermum erythrorhizon (gromwell root) for treating or controlling excessive oil production in skin and minimizing glycation in skin, and methods of using the compositions
FR2701396A1 (fr) Procédé de stabilisation de vésicules de lipide(s) amphiphile(s) et composition pour application topique contenant lesdites vésicules stabilisées.
RU2637408C2 (ru) Содержащие ретиноид композиции для местного применения типа эмульсии "масло в воде"
Scalia et al. Microencapsulation of a cyclodextrin complex of the UV filter, butyl methoxydibenzoylmethane: In vivo skin penetration studies
EP3319583A1 (fr) Compositions destinées à une utilisation topique
US20100136124A1 (en) Nanoparticle-coated capsule formulation for dermal drug delivery
EP2288333B1 (fr) Compositions à base de prostaglandine et son procédé d'utilisation
US20110081387A1 (en) Liposomes encapsulating an oxazolidin-2-one compound
CN114796008A (zh) 一种具有美白保湿功效的超分子组合物的制备方法与应用
FR2754454A1 (fr) Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
Iannuccelli et al. In vivo and in vitro skin permeation of butyl methoxydibenzoylmethane from lipospheres
JP2022523706A (ja) パーソナルケア用途のための液晶脂質粒子の化粧料組成物
EP1100432B1 (fr) Nouvelles utilisations de l'ascorbyl-phosphoryl-cholesterol et compositions permettant de mettre en oeuvre ces nouvelles utilisations
Zhang et al. Solid-in-oil nanodispersion as a novel topical transdermal delivery to enhance stability and skin permeation and retention of hydrophilic drugs l-ascorbic acid
Feng et al. PHENYLETHYL RESORCINOL LOADED IN LIPID NANO VESICLES: A PROMISING WHITENING COSMETIC INGREDIENT
KR102105210B1 (ko) 레티노이드 유도체를 안정화시킨 수중유형 유화 화장료 조성물
Michniak-Kohn et al. Advanced Formulation Techniques Including Innovative Materials

Legal Events

Date Code Title Description
AS Assignment

Owner name: INFINITEC ACTIVOS, S.L., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOURELLE MANCINI, MARISABEL;ELISA ALEA REYES, MARIA;SIGNING DATES FROM 20190405 TO 20190408;REEL/FRAME:053903/0272

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION